Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 20;12(11):3451.
doi: 10.3390/cancers12113451.

Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial

Justin C Brown  1   2   3 , Michael H Rosenthal  4 , Chao Ma  4 , Sui Zhang  4 , Halla S Nimeiri  5 , Nadine J McCleary  4 , Thomas A Abrams  4 , Matthew B Yurgelun  4 , James M Cleary  4 , Douglas A Rubinson  4 , Deborah Schrag  4 , Andrea J Bullock  6 , Jill Allen  7 , Dan Zuckerman  8 , Emily Chan  9 , Jennifer A Chan  4 , Brian Wolpin  4 , Michael Constantine  10 , Douglas J Weckstein  11 , Meredith A Faggen  12 , Christian A Thomas  13 , Chryssanthi Kournioti  14 , Chen Yuan  4 , Hui Zheng  7 , Bruce W Hollis  15 , Charles S Fuchs  16 , Kimmie Ng  4 , Jeffrey A Meyerhardt  4
Affiliations

Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial

Justin C Brown et al. Cancers (Basel). .

Abstract

Skeletal muscle and adipose tissue express the vitamin D receptor and may be a mechanism through which vitamin D supplementation slows cancer progression and reduces cancer death. In this exploratory analysis of a double-blind, multicenter, randomized phase II clinical trial, 105 patients with advanced or metastatic colorectal cancer who were receiving chemotherapy were randomized to either high-dose vitamin D3 (4000 IU) or standard-dose (400 IU) vitamin D3. Body composition was measured with abdominal computed tomography at enrollment (baseline) and after cycle 8 of chemotherapy (16 weeks). As compared with standard-dose vitamin D3, high-dose vitamin D3 did not significantly change body weight [-0.7 kg; (95% CI: -3.5, 2.0)], body mass index [-0.2 kg/m2; (95% CI: -1.2, 0.7)], muscle area [-1.7 cm2; (95% CI: -9.6, 6.3)], muscle attenuation [-0.4 HU; (95% CI: -4.2, 3.2)], visceral adipose tissue area [-7.5 cm2; (95% CI: -24.5, 9.6)], or subcutaneous adipose tissue area [-8.3 cm2; (95% CI: -35.5, 18.9)] over the first 8 cycles of chemotherapy. Among patients with advanced or metastatic colorectal cancer, the addition of high-dose vitamin D3, vs standard-dose vitamin D3, to standard chemotherapy did not result in any changes in body composition.

Keywords: adipose tissue; cholecalciferol; colorectal neoplasms; mediation; prognosis; randomized; skeletal muscle.

PubMed Disclaimer

Conflict of interest statement

J.C.B. reported receiving grants from the National Institutes of Health the American Institute for Cancer Research, and the Susan G. Komen Foundation. H.S.N. reported being employed at AbbVie. T.A.A. reported receiving grants from Eli Lilly and Bristol-Myers Squibb; and receiving personal fees from Bristol-Myers Squibb and Genentech. M.B.Y. reported consulting fees from Janssen Pharmaceuticals and receiving personal fees for peer review services from UpToDate. J.M.C. received research funding to his institution from Abbvie, Merus, Roche, and Bristol Myers Squib; received research funding from Merck, Astrazeneca, Esperas Pharma, and Tesaro; received consulting fees from Bristol Myers Squibb; and received travel funding from Bristol Myers Squib. D.S. reported receiving personal fees from JAMA; receiving grants from Pfizer, the Alliance for Clinical Trials in Oncology, the American Association for Cancer Research, the National Cancer Institute, the Patient-Centered Outcomes Research Institute, and the American Cancer Society; and receiving nonfinancial support from Epic Systems Corporation. A.J.B. reported receiving personal fees from Taiho Oncology, Bayer, Eisai, Exelixis, and Celgene. E.C. reported being employed at Amgen; and receiving funding from Dana-Farber Cancer Institute and owning shares of Amgen stock. J.A.C. reported receiving personal fees from Novartis, Ipsen, Lexicon, AAA, and Exelixis; and receiving support from Novartis, Merck, Sanofi, and Lilly. B.W. reported receiving grants from Celgene; and receiving personal fees from BioLineRx and Grail. C.A.T. reported receiving personal fees from Genetech/ Roche, Bristol-Myers Squibb, and Aztra Zeneca. H.Z. reported receiving grants from the National Institutes of Health. C.S.F. reported receiving personal fees from Eli Lilly, Entrinsic Health, Pfizer, Merck, Sanofi, Roche, Genentech, Merrimack Pharma, Dicerna, Bayer, Celgene, Agios, Gilead Sciences, Five Prime Therapeutics, Taiho, KEW, and CytomX Therapeutics; and receiving support from CytomX Therapeutics. K.N. reported receiving grants from the National Cancer Institute, Genentech, Consano, Gilead Sciences, Tarrex Biopharma, Trovagene, Celgene, and Pharmavite; and receiving personal fees from Genentech, Lilly, Tarrex Biopharma, Bayer, and Seattle Genetics. J.A.M. has received institutional research funding from Boston Biomedical, has served as an advisor/consultant to Ignyta and COTA Healthcare, and served on a grant review panel for the National Comprehensive Cancer Network funded by Taiho Pharmaceutical. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Flow of participants.
See this image and copyright information in PMC

References

    1. Schleicher R.L., Sternberg M.R., Lacher D.A., Sempos C.T., Looker A.C., Durazo-Arvizu R.A., Yetley E.A., Chaudhary-Webb M., Maw K.L., Pfeiffer C.M., et al. The vitamin D status of the US population from 1988 to 2010 using standardized serum concentrations of 25-hydroxyvitamin D shows recent modest increases. Am. J. Clin. Nutr. 2016;104:454–461. doi: 10.3945/ajcn.115.127985. - DOI - PMC - PubMed
    1. Theodoratou E., Tzoulaki I., Zgaga L., Ioannidis J.P. Vitamin D and multiple health outcomes: Umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ. 2014;348:g2035. doi: 10.1136/bmj.g2035. - DOI - PMC - PubMed
    1. Michaelsson K., Baron J.A., Snellman G., Gedeborg R., Byberg L., Sundstrom J., Berglund L., Arnlov J., Hellman P., Blomhoff R., et al. Plasma vitamin D and mortality in older men: A community-based prospective cohort study. Am. J. Clin. Nutr. 2010;92:841–848. doi: 10.3945/ajcn.2010.29749. - DOI - PubMed
    1. Zhang Y., Fang F., Tang J., Jia L., Feng Y., Xu P., Faramand A. Association between vitamin D supplementation and mortality: Systematic review and meta-analysis. BMJ. 2019;366:l4673. doi: 10.1136/bmj.l4673. - DOI - PMC - PubMed
    1. Keum N., Lee D.H., Greenwood D.C., Manson J.E., Giovannucci E. Vitamin D supplementation and total cancer incidence and mortality: A meta-analysis of randomized controlled trials. Ann. Oncol. 2019;30:733–743. doi: 10.1093/annonc/mdz059. - DOI - PMC - PubMed